Recent advances in multimodal treatment for gastric cancer: a review.
Recent advances in multimodal treatment for gastric cancer: a review.
复制标题
DOI：
10.1007/s10120-005-0321-z
复制
发表时间：
2005-01-01
期刊：
影响因子：
--
通讯作者：
Siewert, J Rudiger
中科院分区：
文献类型：
--
作者：
Lordick, Florian;Siewert, J Rudiger
胃癌手术治疗后的预后仍然较差。本综述旨在阐明胃癌多模式治疗的适应症。对重要国际癌症会议上提出的临床数据进行了系统的文献研究和评估。最近发表的大型随机 III 期试验结果强调了新辅助化疗或辅助放化疗在胃癌中的潜在价值。然而，随机对照试验的数据仍然很少，并且仍不确定哪些亚组患者应常规接受多模式治疗。考虑到术前和术后治疗的副作用，有必要对预后和预测标记物进行更明确的定义。新辅助化疗是局部晚期胃癌的一种日益增长的选择。辅助放化疗已被证明对接受次优手术切除的胃癌患者有益。单独辅助化疗的益处似乎很小。
The prognosis after surgical treatment of gastric cancer remains poor. This review aims to clarify the indication for multimodal treatment of gastric cancer. A systematic literature research and evaluation of clinical data presented at important international cancer meetings were undertaken. Recently published results of large randomized phase III trials underscore the potential value of neoadjuvant chemotherapy or adjuvant chemoradiotherapy in gastric cancer. However, data from randomized controlled trials are still scarce, and it remains uncertain which subgroups of patients should routinely undergo multimodal treatment. In view of the side effects of pre- and foremost postoperative therapies, a more distinct definition of prognostic and predictive markers is warranted. Neoadjuvant chemotherapy is a rising option in locally advanced gastric cancer. Adjuvant chemoradiation has been shown to be beneficial in gastric cancer patients who have undergone suboptimal surgical resection. The benefits of adjuvant chemotherapy alone seem to be very small.